Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluticasone /salmeterol Clear all

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Asthma
Interventions: fluticasone, montelukast, Fluticasone plus salmeterol; Drug
Lead sponsor: JHSPH Center for Clinical Trials; Other
Eligibility: 6 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 16 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol, Fluticasone Propionate/Salmeterol Combination Product; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more

Conditions: Asthma
Interventions: FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 38
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more

Conditions: Asthma
Interventions: ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 11,751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 350
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Conditions: Asthma
Interventions: Fluticasone Propionate and Salmeterol Inhalation Powder, Placebo Inhalation Powder; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Asthma, COPD
Interventions: MGR001, Advair® Diskus®, Seretide™ Accuhaler™; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Asthma
Interventions: OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo; Drug
Lead sponsor: Oriel Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 879 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 47
States / cities: Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, UMEC, VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Newport Beach, California • San Diego, California • Upland, California + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more

Conditions: Asthma
Interventions: Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI, Fluticasone propionate/salmeterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Huntington Beach, California • Raleigh, North Carolina • San Antonio, Texas

Conditions: Asthma
Interventions: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 37
States / cities: Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more

Conditions: Asthma
Interventions: Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 47 more

Conditions: Asthma
Interventions: FP 100mcg, FSC 100/50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 141
States / cities: Ozark, Alabama • Tucson, Arizona • Little Rock, Arkansas + 118 more

Conditions: Asthma
Interventions: Tiotropium, Salmeterol, Formoterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,070 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Jacksonville, Florida • Marietta, Georgia • Newton, Georgia + 10 more

Conditions: Asthma
Interventions: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more

Conditions: Asthma
Interventions: Flovent Diskus, Home Environmental Intervention, Advair Diskus; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Altitude Edema
Interventions: Advair HFA, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Obstructive Pulmonary Disease, Depression
Interventions: Advair diskus; Drug
Lead sponsor: Valley Medical Research; Other
Eligibility: 18 Years to 94 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Brooksville, Florida • Centerville, Ohio

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 85
States / cities: Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more

Conditions: Chronic Obstructive Pulmonary Disease, Sleep Disorders
Interventions: salmeterol-fluticasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Fall Epidemic Viral Pediatric Study

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Advair Pediatric Once-Daily

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

MGR001 / Advair Diskus Local Equivalence Study in Asthma

Environmental Control as Add-on Therapy in Childhood Asthma

Advair HFA in Healthy and HAPE Predisposed Subjects

The Effect on Depressive Symptoms in ECF Residents With COPD

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD